• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

尼拉帕利的联合使用增强了抗GD2抗体对骨肉瘤细胞的抑制作用。

Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells.

作者信息

Wenyao Chen, Shuai Ma, Yifeng Fan, Xinzhi Li, Xiangyong Que

机构信息

Affiliated Renhe Hospital of China Three Gorges University, No. 410, Yiling Avenue, Yichang, 443001, China.

出版信息

Discov Oncol. 2024 Jul 24;15(1):304. doi: 10.1007/s12672-024-01166-y.

DOI:10.1007/s12672-024-01166-y
PMID:39048747
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11269552/
Abstract

PURPOSE

This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells.

METHODS

Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate cell invasion potential. Cell proliferation was measured using the CCK8 experiment. The affinity between the anti-GD2 antibody and its antigen was determined via ELISA. Tumor growth was evaluated through animal experiments. Western blotting, QRT-PCR, and histological analysis were conducted to examine the expression of relevant proteins and mRNAs.

RESULTS

MG63 cell line was used for an example. The scratch test showed that the migration rate of osteosarcoma cells in Niraparib + Anti-GD2 group was 1.07 ± 0.04 after 48 h, and 0.34 ± 0.04 in the Control group. Transwell experiment showed that the invasion ability of osteosarcoma cells in Niraparib + Anti-GD2 group was 21.0 ± 1.5, and that in Control group was 87.7 ± 2.9. CCK8 experiment showed that the absorbance value of Niraparib + Anti-GD2 group was 0.16 ± 0.10 on day 5, and that of the Control group was 0.76 ± 0.09. Western blotting showed that the expression levels of BALP and CICP in Niraparib + Anti-GD2 group were 0.751 ± 0.135 and 1.086 ± 0.115, respectively, and those in Control group were 1.025 ± 0.143 and 1.216 ± 0.168, respectively. QRT-PCR results showed that the absorbance values of Niraparib + Anti-GD2 group were 0.173 ± 0.065 and 0.170 ± 0.078 on day 14. The results of animal experiments showed that on day 5, the tumor volume of the Control group was 2433 ± 391, and that of the Niraparib + Anti-GD2 group was 1137 ± 148. Histological analysis showed that the mean density values of Niraparib + Anti-GD2 group were 0.19 ± 0.08 and 0.22 ± 0.07, and those of Control group were 0.26 ± 0.09 and 0.29 ± 0.10.

CONCLUSION

The combination of Niraparib and Anti-GD2 antibody significantly inhibits Osteosarcoma cells.

摘要

目的

本研究旨在探讨尼拉帕利与抗GD2抗体联合应用对骨肉瘤细胞的影响。

方法

采用划痕试验评估细胞迁移能力，采用Transwell实验评估细胞侵袭潜能。使用CCK8实验检测细胞增殖情况。通过ELISA测定抗GD2抗体与其抗原之间的亲和力。通过动物实验评估肿瘤生长情况。进行蛋白质免疫印迹法、定量逆转录聚合酶链反应和组织学分析，以检测相关蛋白质和信使核糖核酸的表达。

结果

以MG63细胞系为例。划痕试验显示，尼拉帕利+抗GD2组骨肉瘤细胞在48小时后的迁移率为1.07±0.04，对照组为0.34±0.04。Transwell实验显示，尼拉帕利+抗GD2组骨肉瘤细胞的侵袭能力为21.0±1.5，对照组为87.7±2.9。CCK8实验显示，尼拉帕利+抗GD2组在第5天的吸光度值为0.16±0.10，对照组为0.76±0.09。蛋白质免疫印迹法显示，尼拉帕利+抗GD2组骨碱性磷酸酶和骨钙素的表达水平分别为0.751±0.135和1.086±0.115，对照组分别为1.025±0.143和1.216±0.168。定量逆转录聚合酶链反应结果显示，尼拉帕利+抗GD2组在第14天的吸光度值分别为0.173±0.065和0.170±0.078。动物实验结果显示，在第5天，对照组的肿瘤体积为2433±391，尼拉帕利+抗GD2组为1137±148。组织学分析显示，尼拉帕利+抗GD2组的平均密度值分别为0.19±0.08和0.22±0.07，对照组分别为0.26±0.09和0.29±0.10。

结论

尼拉帕利与抗GD2抗体联合应用可显著抑制骨肉瘤细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/5e9961663887/12672_2024_1166_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/11dd954a8b89/12672_2024_1166_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/802737833367/12672_2024_1166_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/9ef6f8d81449/12672_2024_1166_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/f8cb528a5f40/12672_2024_1166_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/9f86a2ea1408/12672_2024_1166_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/cd2f5da07dc2/12672_2024_1166_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/5e9961663887/12672_2024_1166_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/11dd954a8b89/12672_2024_1166_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/802737833367/12672_2024_1166_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/9ef6f8d81449/12672_2024_1166_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/f8cb528a5f40/12672_2024_1166_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/9f86a2ea1408/12672_2024_1166_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/cd2f5da07dc2/12672_2024_1166_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f53/11269552/5e9961663887/12672_2024_1166_Fig7_HTML.jpg

相似文献

1
Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells.尼拉帕利的联合使用增强了抗GD2抗体对骨肉瘤细胞的抑制作用。
Discov Oncol. 2024 Jul 24;15(1):304. doi: 10.1007/s12672-024-01166-y.
2
Niraparib Enhances and Synergizes with Ganglioside GD2 to Potentiate its Inhibitory Effect on Bladder Cancer Cells.尼拉帕利增强神经节苷脂GD2的作用并与之协同，以增强其对膀胱癌细胞的抑制作用。
Comb Chem High Throughput Screen. 2024 Oct 1. doi: 10.2174/0113862073343602240909115320.
3
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.靶向 GD2 或 HER2 的 T 细胞衔接双特异性抗体治疗骨肉瘤。
J Hematol Oncol. 2020 Dec 10;13(1):172. doi: 10.1186/s13045-020-01012-y.
4
Curcumin inhibits the proliferation and migration of osteosarcoma by regulating the expression of superenhancerassociated genes.姜黄素通过调节超级增强子相关基因的表达来抑制骨肉瘤的增殖和迁移。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Apr 28;49(4):541-552. doi: 10.11817/j.issn.1672-7347.2024.230224.
5
Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.内皮素 A 受体拮抗作用增强抗神经节苷脂 GD2 单克隆抗体对人骨肉瘤细胞侵袭性和活力的抑制作用。
PLoS One. 2014 Apr 11;9(4):e93576. doi: 10.1371/journal.pone.0093576. eCollection 2014.
6
Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib.莪术醇靶向PAX8抑制卵巢癌细胞迁移和侵袭并增强尼拉帕利的化疗敏感性
J Oncol. 2022 May 2;2022:3941630. doi: 10.1155/2022/3941630. eCollection 2022.
7
MiR-139 inhibits proliferation, migration and invasion of osteosarcoma cell line MG63 via down-regulating integrin subunit alpha V(ITGAV).微小RNA-139通过下调整合素αV亚基（ITGAV）抑制骨肉瘤细胞系MG63的增殖、迁移和侵袭。
Tissue Cell. 2022 Apr;75:101720. doi: 10.1016/j.tice.2021.101720. Epub 2021 Dec 24.
8
[microRNA-16-5p targeted tetraspanin 15 gene to inhibit the proliferation, migration and invasion of osteosarcoma cell through phospoinositide 3-kinase/protein kinase B signaling pathway].[微小RNA-16-5p靶向四跨膜蛋白15基因通过磷脂酰肌醇3-激酶/蛋白激酶B信号通路抑制骨肉瘤细胞的增殖、迁移和侵袭]
Zhonghua Yi Xue Za Zhi. 2020 Jun 2;100(21):1668-1675. doi: 10.3760/cma.j.cn112137-20191101-02376.
9
Positron Emission Tomography Detects Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.正电子发射断层扫描检测原发性和转移性骨肉瘤小鼠模型中二唾液酸神经节苷脂 GD2 的表达。
Cancer Res. 2019 Jun 15;79(12):3112-3124. doi: 10.1158/0008-5472.CAN-18-3340. Epub 2019 Apr 23.
10
Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.抗神经节苷脂GD2单克隆抗体与顺铂协同作用，诱导骨肉瘤细胞发生内质网相关凋亡。
Pharmazie. 2018 Feb 1;73(2):80-86. doi: 10.1691/ph.2018.7836.

本文引用的文献

1
Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions.使用聚（ADP-核糖）聚合酶（PARP）抑制剂奥拉帕尼联合X射线或碳离子对骨肉瘤细胞进行放射增敏作用。
J Cancer. 2024 Jan 1;15(3):699-713. doi: 10.7150/jca.90371. eCollection 2024.
2
A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma.一种具有成骨肉瘤活性的双功能 PARP-HDAC 抑制剂。
Clin Cancer Res. 2023 Sep 1;29(17):3541-3553. doi: 10.1158/1078-0432.CCR-22-3897.
3
GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy.
GD2嵌合抗原受体T细胞（GD2 CAR-T细胞）与纳武单抗联合使用时表现出增强的抗肿瘤疗效。
Transl Oncol. 2023 Jun;32:101663. doi: 10.1016/j.tranon.2023.101663. Epub 2023 Mar 24.
4
New Horizons in the Treatment of Osteosarcoma.骨肉瘤治疗的新视野
N Engl J Med. 2021 Nov 25;385(22):2066-2076. doi: 10.1056/NEJMra2103423.
5
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.尼拉帕利：晚期卵巢癌一线维持治疗的研究进展。
Target Oncol. 2021 Nov;16(6):839-845. doi: 10.1007/s11523-021-00841-2. Epub 2021 Oct 11.
6
Niraparib for Advanced Breast Cancer with Germline and Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.尼拉帕利治疗种系和突变的晚期乳腺癌：EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO 研究。
Clin Cancer Res. 2021 Oct 15;27(20):5482-5491. doi: 10.1158/1078-0432.CCR-21-0310. Epub 2021 Jul 22.
7
plus Suppress the Growth of Non-Small-Cell Lung Cancer via NLRP3/NF-B/MAPK Signaling Pathways.plus通过NLRP3/NF-κB/MAPK信号通路抑制非小细胞肺癌的生长。
Evid Based Complement Alternat Med. 2021 Jun 14;2021:6666499. doi: 10.1155/2021/6666499. eCollection 2021.
8
Advancing therapy for osteosarcoma.骨肉瘤的前沿治疗
Nat Rev Clin Oncol. 2021 Oct;18(10):609-624. doi: 10.1038/s41571-021-00519-8. Epub 2021 Jun 15.
9
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.尼拉帕利作为一线化疗后广泛期小细胞肺癌患者维持治疗的疗效和安全性：一项随机、双盲、III 期研究。
J Thorac Oncol. 2021 Aug;16(8):1403-1414. doi: 10.1016/j.jtho.2021.04.001. Epub 2021 Apr 26.
10
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.利用神经节苷脂和细胞表面波形蛋白的组合作为表面生物标志物，在微流控装置中分离骨肉瘤细胞。
J Bone Oncol. 2021 Mar 24;28:100357. doi: 10.1016/j.jbo.2021.100357. eCollection 2021 Jun.